BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 17124058)

  • 1. FLT3 mutations: biology and treatment.
    Small D
    Hematology Am Soc Hematol Educ Program; 2006; ():178-84. PubMed ID: 17124058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting FLT3 for the treatment of leukemia.
    Small D
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S17-21. PubMed ID: 18760705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
    Sattler M; Scheijen B; Weisberg E; Griffin JD
    Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FLT3 inhibition as a targeted therapy for acute myeloid leukemia.
    Sanz M; Burnett A; Lo-Coco F; Löwenberg B
    Curr Opin Oncol; 2009 Nov; 21(6):594-600. PubMed ID: 19684517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.
    Whitman SP; Archer KJ; Feng L; Baldus C; Becknell B; Carlson BD; Carroll AJ; Mrózek K; Vardiman JW; George SL; Kolitz JE; Larson RA; Bloomfield CD; Caligiuri MA
    Cancer Res; 2001 Oct; 61(19):7233-9. PubMed ID: 11585760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A study of NPM1 and FLT3 gene mutations in acute myeloid leukemia].
    Wu DP; Yan LZ; Yang L; Chen SN; Wu XJ; Liang JY
    Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):907-10. PubMed ID: 18261272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy.
    Tiesmeier J; Müller-Tidow C; Westermann A; Czwalinna A; Hoffmann M; Krauter J; Heil G; Ganser A; Serve H; Verbeek W
    Leuk Res; 2004 Oct; 28(10):1069-74. PubMed ID: 15289019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [FMS-like tyrosine kinase 3 gene mutations in acute myeloid leukemia].
    Han YL; Zhang SJ; Qiao C; Dai D; Sun XM; Xu YL; Qian SX; Xu W; Wang JS; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1135-9. PubMed ID: 19840437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients.
    Andersson A; Johansson B; Lassen C; Mitelman F; Billström R; Fioretos T
    Eur J Haematol; 2004 May; 72(5):307-13. PubMed ID: 15059064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.
    Levis M; Tse KF; Smith BD; Garrett E; Small D
    Blood; 2001 Aug; 98(3):885-7. PubMed ID: 11468194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
    Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
    Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
    Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
    Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).
    Schittenhelm MM; Yee KW; Tyner JW; McGreevey L; Haley AD; Town A; Griffith DJ; Bainbridge T; Braziel RM; O'Farrell AM; Cherrington JM; Heinrich MC
    Leukemia; 2006 Nov; 20(11):2008-14. PubMed ID: 16990784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
    Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
    Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation.
    Yoshimoto G; Nagafuji K; Miyamoto T; Kinukawa N; Takase K; Eto T; Kato K; Hayashi S; Kamimura T; Ohno Y; Taniguchi S; Harada M
    Bone Marrow Transplant; 2005 Dec; 36(11):977-83. PubMed ID: 16184177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy.
    Boissel N; Cayuela JM; Preudhomme C; Thomas X; Grardel N; Fund X; Tigaud I; Raffoux E; Rousselot P; Sigaux F; Degos L; Castaigne S; Fenaux P; Dombret H
    Leukemia; 2002 Sep; 16(9):1699-704. PubMed ID: 12200684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
    Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
    Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.